A Clinical Update on ST316 & Lucicebtide, First-In- Class Peptide Antagonists of β-catenin/BCL9 and C/EBPβ, in Colorectal Cancer & Glioblastoma
- Presenting a clinical update on ST316, including the latest data from ongoing Phase 2 clinical program in colorectal cancer
- Spotlighting a clinical update on lucicebtide, including latest data update from Phase 2 clinical program in glioblastoma
NEW DATA